|Pack Size||Availability||Price (USD)|
Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0
Solubility: Soluble in DMSO
Storage: 0 - 4°C for short term (days to weeks), or -20°C for long term (months).
Linagliptin, also known as BI-1356, is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes. Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes. It is being marketed by Boehringer Ingelheim and Lilly.